KALA BIO signs USD 15 million LOI. KALA BIO stock sits 99.3 percent below its opening price

Published on 10/16/2026 at 02:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The target posted USD 12.7 million in trailing revenue through August 2026. Short interest in KALA BIO stock reached 1,358,824 shares on September 30, 2026.

Telehealth expansion and valuation

KALA BIO signed a USD 15 million telehealth letter of intent on September 29, 2026.
The target generated USD 12.7 million in trailing revenue through August 2026.
KALA BIO had a USD 3.7 million market capitalization as of October 16, 2026.

KALA BIO stock, healthcare, telehealth acquisition, short interest, NASDAQ, Nasdaq Composite, Illustration mit AI erstellt.

KALA BIO signed a non-binding letter of intent on September 24, 2026, to acquire a nationwide telehealth platform in a transaction valued at USD 15 million, as Investing.com reported on September 29, 2026. The proposed deal gives the biotechnology company a concrete route beyond its legacy ophthalmology programs.

Telehealth deal sets the frame

The target generated USD 12.7 million in unaudited trailing revenue through August 2026 and had served more than 90,000 clients since its founding in 2023, according to Investing.com. The same report said sales since inception exceeded USD 48 million, while the transaction would combine cash and KALA stock.

The acquisition remains a proposal rather than a completed transaction. KALA BIO's website says the company is developing Researgency.ai, an enterprise agentic platform for biopharmaceutical research, alongside work on legacy clinical data.

What does the transaction add?

The deal would place a platform with USD 12.7 million of trailing revenue beside KALA BIO's research and data strategy. That comparison matters because the company reported no revenue estimate on its latest market profile, while its proposed acquisition carries a specific operating base.

MarketBeat reported that short interest reached 1,358,824 shares on September 30, 2026, up 205.1 percent from September 15. Its report also cited a consensus Sell rating based on one analyst rating and said the stock had declined 99.3 percent from its opening level for the year.

Next date is November 3

KALA BIO's 2026 annual meeting is scheduled for November 3, 2026, according to the company calendar shown by MarketBeat. The same calendar lists November 10, 2026 as the estimated next earnings date.

Market value remains compressed

KALA BIO had a market capitalization of USD 3.7 million as of October 16, 2026. The stock's 52-week range was USD 0.12 to USD 95.50 on October 15, 2026, placing the latest USD 0.19 Nasdaq quote near the lower end of that span.

KALA BIO was last at USD 0.19 on Nasdaq on October 15, 2026 at 4:00 p.m. ET, while its market capitalization stood at USD 3.7 million as of October 16, 2026.